Arrowhead Pharmaceuticals (ARWR) Change in Acquisitions & Divestments (2016 - 2025)
Arrowhead Pharmaceuticals' Change in Acquisitions & Divestments history spans 15 years, with the latest figure at $115.3 million for Q4 2025.
- For Q4 2025, Change in Acquisitions & Divestments fell 2.4% year-over-year to $115.3 million; the TTM value through Dec 2025 reached $686.8 million, up 60.83%, while the annual FY2025 figure was $689.6 million, 55.9% up from the prior year.
- Change in Acquisitions & Divestments reached $115.3 million in Q4 2025 per ARWR's latest filing, up from $101.8 million in the prior quarter.
- In the past five years, Change in Acquisitions & Divestments ranged from a high of $240.5 million in Q2 2025 to a low of $13.1 million in Q1 2021.
- Average Change in Acquisitions & Divestments over 5 years is $96.6 million, with a median of $85.9 million recorded in 2023.
- Peak YoY movement for Change in Acquisitions & Divestments: skyrocketed 314.72% in 2021, then tumbled 46.4% in 2023.
- A 5-year view of Change in Acquisitions & Divestments shows it stood at $38.3 million in 2021, then skyrocketed by 81.39% to $69.4 million in 2022, then soared by 92.31% to $133.5 million in 2023, then decreased by 11.48% to $118.2 million in 2024, then fell by 2.4% to $115.3 million in 2025.
- Per Business Quant, the three most recent readings for ARWR's Change in Acquisitions & Divestments are $115.3 million (Q4 2025), $101.8 million (Q3 2025), and $240.5 million (Q2 2025).